7.2 Inappropriate Prescribing & Duplicate Therapy
Key Takeaways
Inappropriate prescribing includes therapy that is unnecessary, contraindicated for the patient, mismatched to the indication, or continued beyond a valid duration
Duplicate therapy means two or more agents that provide overlapping pharmacologic effect—same drug, same class, or same therapeutic purpose—without a justified combination regimen
Same-class duplicates (two ACE inhibitors, two SSRIs, two NSAIDs) are high-yield technician screens during PMR and CMR preparation
Therapeutic duplication can also cross brand/generic names or Rx/OTC pairs (e.g., prescription ibuprofen plus OTC naproxen)
Technicians document both agents and escalate; pharmacists decide whether to discontinue, reconcile, or confirm intentional combination therapy with the prescriber
Inappropriate Prescribing & Duplicate Therapy
Quick Answer: Inappropriate prescribing means a drug is unnecessary, contraindicated, poorly matched to the indication, or continued without a valid reason. Duplicate therapy means overlapping agents—same drug, same class, or same therapeutic goal—appear together without justification. Technicians screen for these patterns on PMRs and claim histories and escalate to the pharmacist.
Official Domain 2 knowledge for the PTCB MTM Certificate pairs types of prescribing errors with inappropriate prescribing and related medication problems. Duplicate therapy is one of the most common, exam-friendly patterns you will catch during systematic profile review.
Inappropriate Prescribing: What “Doesn’t Belong”
Inappropriate prescribing is broader than a single wrong digit on a dose. It asks whether the drug should be on the regimen at all for this patient at this time.
| Pattern | Screening clue | Example |
|---|---|---|
| No valid indication | Drug persists after the problem resolved | Proton pump inhibitor continued months after a short steroid course with no GI diagnosis |
| Contraindicated for patient factors | Allergy, pregnancy category concerns per policy, severe organ impairment flags | NSAID continued in a patient with prior NSAID-related GI bleed and current anticoagulation |
| Mismatched indication | Drug class does not fit documented condition | Antibiotic prescribed for a documented viral URI with no bacterial findings noted |
| Duration inappropriate | Acute therapy never stopped | “Take until gone” antibiotic still active on profile six weeks later |
| High-risk in special populations | Older adult on potentially inappropriate agent (preview for Beers Criteria chapter) | Long-acting benzodiazepine newly started in a frail 82-year-old for insomnia |
You do not make the final clinical call that a drug is “inappropriate.” You notice the mismatch between history and therapy, capture the evidence, and escalate. That distinction keeps you inside the technician scope while still protecting patients.
Scenario: During CMR prep, the active list shows cyclobenzaprine started after a motor vehicle accident two years ago, with no recent musculoskeletal notes and the patient saying “I only take it if I remember.” That may be unnecessary chronic therapy, an adherence issue, or both. Flag for pharmacist review rather than deleting the line yourself.
Duplicate Therapy Defined
Duplicate therapy (also called therapeutic duplication) occurs when two or more medications provide essentially the same pharmacologic effect or treat the same problem in an overlapping way without a deliberate, evidence-based combination strategy.
Three layers to remember:
- Same drug duplication — identical molecule from two sources (brand and generic both active; two pharmacies filling the same API).
- Same-class duplication — two drugs from one pharmacologic class (lisinopril + enalapril; sertraline + fluoxetine).
- Same-goal therapeutic duplication — different classes, overlapping purpose (two full-dose anticoagulants; ibuprofen + naproxen for pain).
Intentional combinations exist (e.g., some heart-failure regimens use complementary mechanisms). Your job is to surface the overlap. The pharmacist decides whether it is intentional, outdated, or dangerous.
Same-Class Duplicates: High-Yield Screen List
| Class | Duplicate example | Why it matters |
|---|---|---|
| ACE inhibitors | Lisinopril + ramipril | Excess hypotension, hyperkalemia, AKI risk |
| ARBs | Losartan + valsartan | Similar hemodynamic/electrolyte risks |
| Beta blockers | Metoprolol + atenolol (unintended) | Bradycardia, hypotension |
| SSRIs / SNRIs | Sertraline + escitalopram | Serotonin excess, side effects |
| Statins | Atorvastatin + simvastatin | Myopathy risk without benefit |
| Benzodiazepines | Alprazolam + clonazepam | Falls, sedation, dependence |
| NSAIDs (Rx or OTC) | Ibuprofen + naproxen | GI bleed, kidney injury |
| Antihistamines (sedating) | Diphenhydramine + doxylamine | Anticholinergic / fall risk |
| PPIs | Omeprazole + pantoprazole | Unnecessary acid suppression |
| Insulins (uncoordinated) | Two basal regimens from different prescribers | Hypoglycemia |
Exam tip: stems that list two agents from one row above almost always want you to recognize therapeutic duplication and escalate to the pharmacist—not pick which one to stop yourself.
Cross-Product and Hidden Duplicates
Duplicates hide in messy real-world lists:
- Brand/generic twins: Coumadin and warfarin both marked active.
- Combination products: Hydrocodone/acetaminophen plus separate acetaminophen OTC → acetaminophen duplication and hepatotoxicity risk.
- Rx + OTC overlap: Prescription diclofenac gel plus oral ibuprofen.
- Multi-prescriber chaos: Cardiologist ACE inhibitor + primary care ARB after incomplete reconciliation.
- Mail-order + local pharmacy: Same statin filled in both channels with overlapping days’ supply.
Scenario: PMR draft shows “Advil Migraine” (OTC) and “ibuprofen 800 mg” (Rx). Different labels, same NSAID exposure. Document both product names, total daily NSAID burden if known, and escalate. Do not assume OTC lines are unimportant.
Inappropriate vs Duplicate vs Prescribing Error
Keep the vocabulary clean for exam items:
| Term | Focus |
|---|---|
| Prescribing error (order defect) | Wrong dose, strength, drug, route, directions, timing, or missing dose fields |
| Inappropriate prescribing | Drug should not be used (or continued) for this patient/indication/duration |
| Duplicate therapy | Overlapping agents without justified combination |
One profile can show all three. Example: two ACE inhibitors (duplicate) at an extreme combined dose (abnormal dose) in a patient with prior angioedema to an ACE inhibitor (inappropriate/contraindicated). Escalate the whole picture; do not argue taxonomy with the patient.
Workflow: How Technicians Handle Findings
- Identify both agents (or the inappropriate single agent) with strengths and directions.
- Check start dates, prescribers, and whether one was supposed to replace the other.
- Ask clarifying history only as allowed by site protocol (“Are you still taking both blood pressure pills?”).
- Document on the working PMR/CMR notes exactly what was found.
- Escalate to the pharmacist before releasing related fills or finalizing patient-facing materials that imply both are intentional.
- Support pharmacist follow-up: holds, clarification calls, MAP updates after the clinical decision.
Never discontinue a chronic medication on technician authority because it “looks duplicate.” Stopping the wrong agent can cause rebound hypertension, withdrawal, or loss of control.
Connection to Adherence and Cost
Duplicates inflate pill burden and cost, which then worsen adherence. A patient paying two copays for overlapping antidepressants may skip both. Flagging duplication can improve safety and affordability in one pharmacist intervention. When you screen, note cost comments alongside the therapeutic overlap so the pharmacist can prioritize.
Inappropriate and duplicate therapy screening is one of the highest-value technician contributions to MTM quality. Catch the overlap early, escalate clearly, and leave deprescribing decisions to the pharmacist and prescriber.
A patient’s active PMR lists lisinopril 20 mg daily and ramipril 5 mg daily from two different clinics. This is best classified as:
An adherence calculation error only
Same-class therapeutic duplication requiring pharmacist escalation
A missing-dose prescribing error because frequencies match
Appropriate dual ACE inhibitor therapy that technicians should reinforce
Which finding is the clearest example of inappropriate prescribing rather than simple same-molecule duplication?
Warfarin and Coumadin both marked active on the profile
Atorvastatin filled at mail order and again at a local pharmacy under the same directions
A PPI continued for nine months after a short steroid course with no documented ongoing GI indication
Sertraline listed twice with identical strength and sig from one pharmacy
During intake, a patient reports daily OTC naproxen plus prescription ibuprofen 800 mg three times daily for arthritis. What should the technician do first?
Advise the patient to stop the naproxen immediately and continue only ibuprofen
Ignore OTC products because they are not on the prescription profile
Add both to the working medication list, note NSAID overlap, and escalate to the pharmacist
Switch both agents to acetaminophen without pharmacist review
Why must technicians escalate suspected duplicates instead of deleting one drug from the PMR on their own?
Because some overlapping regimens are intentional, and stopping the wrong agent can harm the patient
Because duplicate therapy is never clinically important
Because only insurance plans can change medication lists
Because PMRs are not allowed to list more than one blood pressure drug
Sections you finish are checked off in the contents.